Bioinformatic identification of a fatty acid metabolism-related gene signature for prognosis prediction and drug sensitivity assessment in osteosarcoma
Introduction: Osteosarcoma is an aggressive malignancy with high metastatic potential, leading to poor prognosis in recurrent and metastatic cases. Objectives: This study aimed to identify prognostic fatty acid metabolism-related genes (FAMRGs) in osteosarcoma and characterize the clinical and biological features of ACSF2. Methods: Transcriptomic and clinical data from Therapeutically Applicable Research to Generate Effective Treatments–Osteosarcoma, Genotype-Tissue Expression, and GSE16088 were analyzed. Consistently differentially expressed FAMRGs were screened via dual-cohort validation. Least absolute shrinkage and selection operator and Cox regression analyses were used to select prognostic genes, with overall survival (OS) as the primary endpoint and event-free survival (EFS) as the secondary endpoint. An ACSF2-based prognostic model combined with metastatic status was internally validated by bootstrap resampling. Gene Set Enrichment Analysis, OncoPredict, ESTIMATE, and CIBERSORT analyses were performed to explore ACSF2-associated pathways, drug sensitivity, and immune infiltration. In vitro functional assays were conducted to verify the biological function of acyl-CoA synthetase family member 2 (ACSF2). Results: Four prognostic FAMRGs were screened from 15 consistently dysregulated genes. Low ACSF2 expression independently predicted inferior OS and EFS, without significant correlation with diagnostic metastasis. The optimized model yielded a corrected C-index of 0.729 and a calibration slope of 0.943. ACSF2 was closely associated with fatty acid and mitochondrial metabolism. The ACSF2-high subgroup showed higher predicted sensitivity to Uprosertib and MN-64 and exhibited distinct immune infiltration patterns. Functional experiments confirmed that elevated ACSF2 expression suppresses the migration and invasion of human osteosarcoma cells. Conclusion: ACSF2 is a promising candidate prognostic biomarker for osteosarcoma. Its metabolic, pharmacological, and immune correlations are exploratory and require further experimental validation.
Authors
- Chuanzhi Zhang
- Changsheng Zhang
- Hao Gu
- Yu Li
- Xiao Shi
- Xinxin Si
Institutions
- Lianyungang Runzhong Pharmaceutical (China) (CN)
Publication Details
- Journal
- Eurasian Journal of Medicine and Oncology
- Published
- 2026-11-17
- DOI
- https://doi.org/10.36922/ejmo026310397
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Priority Academic Program Development of Jiangsu Higher Education Institutions